Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | CES2 | O00748 | 3/20 | 0.54 |
| ▸ | CES1 | P23141 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL9836167 | 0.98 | ALDH1A1 (0.52) | ALDH1A1CES2CES1LMNAGAA | |
| SCHEMBL5637913 | 0.93 | ALDH1A1 (0.62) | ALDH1A1CES2CES1LMNAGAA | |
| SCHEMBL2310 | 0.93 | ALDH1A1 (0.62) | ALDH1A1CES2CES1LMNAGAA | |
| SCHEMBL6668626 | 0.86 | ALDH1A1 (0.54) | ALDH1A1CES2CES1LMNAGAA | |
| Benzoyl Chloride SCHEMBL1397148 | 0.84 | CES2 (0.68) | ALDH1A1CES2CES1LMNASMN1; SMN2 | |
| SCHEMBL27554623 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CES2CES1LMNAGAA | |
| Diethylamine SCHEMBL10372653 | 0.81 | ALDH1A1 (0.45) | ALDH1A1CES2CES1LMNAGAA | |
| Dimethylamine SCHEMBL27770145 | 0.81 | CES2 (0.54) | ALDH1A1CES2CES1LMNASMN1; SMN2 | |
| Toluene SCHEMBL29163900 | 0.81 | CES2 (0.58) | ALDH1A1CES2CES1LMNASMN1; SMN2 | |
| SCHEMBL14984235 | 0.80 | MAPT (0.60) | ALDH1A1CES2CES1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104689809-B | Preparation and application of positive charge type polysaccharide derivative chiral stationary phase | 台州学院 | 2017-04-26 | — | — | CN | claimed |
| CN-104689809-A | Preparation and application of positive charge type polysaccharide derivative chiral stationary phase | UNIV TAIZHOU | 2015-06-10 | — | — | CN | claimed |
| CN-104689809-B | Preparation and application of positive charge type polysaccharide derivative chiral stationary phase | 台州学院 | 2017-04-26 | — | — | CN | disclosed |
| CN-104689809-A | Preparation and application of positive charge type polysaccharide derivative chiral stationary phase | UNIV TAIZHOU | 2015-06-10 | — | — | CN | disclosed |
| US-20040009923-A1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | DOLLE ROLAND E (US) | 2004-01-15 | — | — | US | disclosed |
| US-6576614-B1 | Administering methyl ketones or closed hemiketal derivatives of aspartic acid | VERTEX PHARMACEUTICALS INCORPORATED | 2003-06-10 | — | — | US | disclosed |
| EP-0623592-B1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | VERTEX PHARMA (US) | 2001-06-27 | — | — | EP | disclosed |
| US-5985838-A | TREATING INFECTIOUS DISEASE, RESPIRATORY DISEASE, INFLAMMATORY CONDITIONS, IMMUNE-BASED DISEASE, AUTO-IMMUNE DISEASE, BONE DISEASE, AND TUMORS | VERTEX PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| US-5843905-A | Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0644197-B1 | Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors | VERTEX PHARMA (US) | 1998-09-09 | — | — | EP | disclosed |
| US-5677283-A | α-heteroaryloxymethyl ketones as interleukin - 1 β converting enzyme inhibitors | SANOFI (FR) | 1997-10-14 | — | — | US | disclosed |
| US-5585357-A | Heteroaryloxymethyl ketones as interleukin-1βconverting enzyme inhibitors | SANOFI WINTHROP INC. (US) | 1996-12-17 | — | — | US | disclosed |
| EP-0644198-A1 | Alpha-heteroaryloxymethyl ketones as interleukin-1beta converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1995-03-22 | — | — | EP | disclosed |
| EP-0644197-A1 | Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1995-03-22 | — | — | EP | disclosed |
| EP-0623592-A1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | STERLING WINTHROP INC. (US) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009923-A1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | IL1B, IL1A, IL1RN | ALDH1A1 674/4885CES2 2661/4885CES1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.